Vir Biotechnology マネジメント
マネジメント 基準チェック /34
Vir Biotechnologyの CEO はMarianne De Backerで、 Apr2023年に任命され、 の在任期間は 3.42年です。 の年間総報酬は$ 7.83Mで、 12.1%給与と87.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.59%を直接所有しており、その価値は$ 10.63M 。経営陣と取締役会の平均在任期間はそれぞれ3.3年と6.9年です。
主要情報
Marianne De Backer
最高経営責任者
US$7.8m
報酬総額
| CEO給与比率 | 12.13% |
| CEO在任期間 | 3.4yrs |
| CEOの所有権 | 0.6% |
| 経営陣の平均在職期間 | 3.3yrs |
| 取締役会の平均在任期間 | 6.9yrs |
経営陣の近況
Recent updates
ナラティブ更新 • Aug 08
VIR: Hepatitis Delta Opportunity Will Support Future Upside Despite Execution Concerns
Analysts have trimmed the fair value estimate for Vir Biotechnology to $15.00 from $16.00, reflecting a lower $25 price target and updated views on slower revenue growth in hepatitis delta virus therapies, while maintaining confidence in the company's positioning in this underdiagnosed market. Analyst Commentary Recent Street research on Vir Biotechnology shows a mix of optimism about the hepatitis delta virus opportunity and more cautious signals on execution and valuation.ナラティブ更新 • Jul 08
VIR: Hepatitis Delta Therapies Will Drive Upside Despite Underdiagnosis Risk
Analysts have raised their fair value estimate for Vir Biotechnology from $12.00 to $16.00, citing a more moderate expected revenue decline, slightly stronger profit margins, and a much lower implied future P/E multiple, along with recent Street research highlighting potential upside from hepatitis delta virus therapies. Analyst Commentary on Vir Biotechnology Recent research on Vir Biotechnology highlights both optimism around hepatitis delta virus therapies and a more cautious undercurrent that centers on execution and valuation risk.
ナラティブ更新 • Jun 23
VIR: Hepatitis Delta Program And Oncology Partnership Will Drive Future Upside
Analysts have lifted the average price target for Vir Biotechnology to about $21.56 from $20.67, citing a slightly higher revenue growth outlook and a richer future P/E assumption as they factor in potential benefits from emerging hepatitis delta virus therapies following recent U.S. approval of bulevirtide. Analyst Commentary Recent research on Vir Biotechnology points to a more constructive stance on the stock, with the updated price target anchored in expectations around the hepatitis delta virus opportunity and how effectively the company can turn that pipeline into commercial revenue.分析記事 • Jun 21
Vir Biotechnology (VIR) Stock Could Be 56% Undervalued After New PSMA Data
Clinical PSMA Data Sparks Fresh Look At Vir Biotechnology Stock Vir Biotechnology (VIR) has moved back onto investors' radars after new PSMA clinical data in prostate cancer prompted an updated investment thesis and renewed focus on the company’s T cell engager pipeline. See our latest analysis for Vir Biotechnology. At a share price of US$9.16, Vir Biotechnology’s short term picture reflects a mix of optimism and caution, with a 7 day share price return of 6.39% and a year to date share...ナラティブ更新 • Jun 04
VIR: Oncology Partnership And Prostate Cancer Data Will Support Future Upside
The analyst consensus price target for Vir Biotechnology has edged down by $1 to reflect updated views on the company, with analysts citing the latest Morgan Stanley research as part of their rationale. What's in the News Superstring Capital Management opened a new US$6m position in Vir Biotechnology, acquiring more than 730,000 shares as part of a broader focus on the company’s clinical programs and partnerships.Seeking Alpha • May 16
Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity
Summary Vir Biotechnology is rated a buy, supported by a strong cash position, pivotal late-stage pipeline, and deep institutional backing. VIR's lead CHD drugs, Tobevibart and Elebsiran, target a large, underserved market with potential for high margins and accelerated regulatory approval. The Astellas partnership secures funding for oncology development, extends the cash runway into 2028, and minimizes dilution risk ahead of key catalysts. With shares trading near cash value and major catalysts in 2026–2028, VIR offers asymmetric upside if pivotal trials succeed. Read the full article on Seeking Alpha分析記事 • May 11
Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next
There's been a notable change in appetite for Vir Biotechnology, Inc. ( NASDAQ:VIR ) shares in the week since its...ナラティブ更新 • May 04
VIR: Oncology Partnership And Prostate Cancer Data Will Drive Future Upside
Narrative Update: Vir Biotechnology Analyst Price Targets Analysts have lifted their average price target on Vir Biotechnology by several dollars to reflect the Astellas collaboration, encouraging VIR-5500 Phase 1 prostate cancer data, and faster than expected progress in hepatitis D, while also incorporating a higher future P/E assumption and slightly lower margin expectations into their models. Analyst Commentary Recent Street research on Vir Biotechnology clusters around a common theme, with multiple firms lifting price targets after the Astellas collaboration and updated VIR-5500 data.ナラティブ更新 • Apr 20
VIR: Oncology Collaboration And Prostate Cancer Data Will Support Future Upside
Analysts have generally lifted their price targets on Vir Biotechnology into a $17 to $30 range, citing the Astellas collaboration, early VIR-5500 oncology data, and progress in hepatitis D as key reasons for the higher valuations. Analyst Commentary Recent Street research skews clearly positive on Vir Biotechnology, with several firms lifting price targets into the high teens to low thirties after reviewing oncology and hepatitis D updates and the Astellas partnership.ナラティブ更新 • Apr 05
VIR: Oncology Partnership And Prostate Cancer Data Will Drive Future Upside
Analysts have raised their price targets on Vir Biotechnology to a range of roughly $17 to $30, citing the Astellas collaboration, encouraging VIR-5500 oncology data, and progress in the hepatitis D program as key reasons for updating their views. Analyst Commentary Recent research shows a clear skew toward optimism on Vir Biotechnology, with several firms lifting their price targets and reassessing the company around its oncology and hepatitis D franchises.ナラティブ更新 • Mar 21
VIR: Oncology Partnership And Hepatitis Delta Progress Will Drive Future Upside
Narrative Update: Vir Biotechnology Analyst Price Target Shift The Street has adjusted its view on Vir Biotechnology, with the consolidated analyst price target now in the high teens to around $20. Analysts cite the Astellas collaboration, VIR-5500 Phase 1 data in prostate cancer, and progress in hepatitis D as key reasons for the reassessment.ナラティブ更新 • Mar 06
VIR: Oncology Partnership And Hepatitis Delta Data Will Drive Future Upside Repricing
Analysts have lifted their average fair value estimate for Vir Biotechnology to about $20.78 from $16.56, as recent price target hikes highlight growing confidence in the Astellas oncology collaboration, VIR-5500 prostate cancer data and progress in hepatitis D. Analyst Commentary Recent research updates show a clear shift in how Wall Street is framing Vir Biotechnology, with a cluster of higher price targets and one downgrade earlier in the period reflecting both stronger conviction around oncology and hepatitis D, and some lingering questions about execution and risk.ナラティブ更新 • Feb 19
VIR: SOLSTICE Hepatitis Delta Data Will Drive Future Upside Repricing Potential
Analysts have slightly increased their price expectations for Vir Biotechnology, with the average fair value estimate rising by about $0.22 to $16.56 as recent VIR-5500 oncology optionality and SOLSTICE 96-week hepatitis delta data are incorporated into updated models. Analyst Commentary Recent research updates on Vir Biotechnology reflect a mix of optimism around the company’s clinical data and pipeline optionality, balanced against questions about long term execution and valuation risk.ナラティブ更新 • Feb 05
VIR: SOLSTICE Hepatitis Delta Data Will Drive Future Repricing Potential
Narrative Update Analysts have trimmed their fair value estimate for Vir Biotechnology from about $17.63 to $16.33 as they factor in higher perceived risk via an increased discount rate. This comes even as they acknowledge stronger revenue growth assumptions, wider profit margins, and updated views on valuation multiples following recent SOLSTICE data and price target revisions from the Street.分析記事 • Nov 10
Some Analysts Just Cut Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates
The analysts covering Vir Biotechnology, Inc. ( NASDAQ:VIR ) delivered a dose of negativity to shareholders today, by...分析記事 • Aug 09
Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
As you might know, Vir Biotechnology, Inc. ( NASDAQ:VIR ) last week released its latest quarterly, and things did not...分析記事 • May 11
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts
It's been a mediocre week for Vir Biotechnology, Inc. ( NASDAQ:VIR ) shareholders, with the stock dropping 17% to...
新しいナラティブ • Mar 23
Strong Clinical Advances In Oncology And Hepatitis Delta Will Secure Future Success
ECLIPSE Phase III program in hepatitis delta and oncology advancements promise revenue and earnings growth through new treatments and diversified revenue streams.Seeking Alpha • Mar 04
Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology
Summary Vir Biotechnology's T-cell engagers have potential in oncology and showed promise with initial data in January 2025, but the stock's rally has since faded. Additional data from the MARCH Part B trial for chronic hepatitis B is expected in Q2'25, but the company won't develop further there without a partner. VIR hasn't provided an exact timeline for the next update from its T-cell engager work, although the company plans to initiate work with a third T-cell engager in 2025. Read the full article on Seeking AlphaSeeking Alpha • Jan 09
Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong?
Summary Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion, raising questions about the sustainability and justification of this valuation. The early data for their T cell engagers suggest favorable safety, with hints of efficacy and a boatload more patients in phase 1 waiting for more evaluation. On balance, at these price levels, VIR stock is attractive, though risky. Read the full article on Seeking Alpha分析記事 • Jan 07
Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Seeking Alpha • Dec 13
Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January
Summary VIR's is expected to report data in January from two phase 1 trials of VIR-5500 and VIR-5818, two T-cell engagers, in various cancer types. JANX recently produced promising data with JANX007, which is similar to VIR-5500, in prostate cancer. As for elebsiran and tobevibart, two treatments for hepatitis B and hepatitis delta, a phase 3 program in hepatitis delta will get underway in H1'25. Read the full article on Seeking AlphaSeeking Alpha • Nov 05
Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off
Summary VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. However, VIR also pivoted to oncology, discontinuing vaccines and viral immunotherapy, and partnered with Sanofi to leverage its PRO-XTEN platform for T-cell engagers. The strategic shift includes a 25% workforce reduction, saving $50 million annually by 2025, and focuses on advancing hepatitis delta and B treatments. I believe its valuation remains attractive, with $909 million in liquidity and no financial debt, despite a high cash burn rate that suggests a potential dilution by 2026 or 2027. Still, I reiterate a "Buy" rating for VIR due to its promising HDV and HBV programs, cost-saving measures, and substantial cash for maneuvering as needed. Read the full article on Seeking Alpha分析記事 • Nov 04
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts
It's shaping up to be a tough period for Vir Biotechnology, Inc. ( NASDAQ:VIR ), which a week ago released some...分析記事 • Sep 08
Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...分析記事 • Aug 03
Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results
It's shaping up to be a tough period for Vir Biotechnology, Inc. ( NASDAQ:VIR ), which a week ago released some...Seeking Alpha • Jul 17
Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis
Summary VIR develops medicines for infectious and viral diseases using proprietary platforms for monoclonal antibodies and T cell-based Viral Vectors. Positive Phase 2 trial results for chronic hepatitis delta highlight the company's potential to address unmet medical needs. Strategic collaborations include the Bill & Melinda Gates Foundation, Alnylam Pharmaceuticals, and Gilead Sciences. The company has substantial liquid resources and no financial debt, supporting a compelling valuation. I believe VIR is undervalued tapping into significant TAMs, making it a "strong buy." Read the full article on Seeking AlphaCEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$252m |
| Mar 31 2026 | n/a | n/a | -US$443m |
| Dec 31 2025 | US$8m | US$950k | -US$438m |
| Sep 30 2025 | n/a | n/a | -US$500m |
| Jun 30 2025 | n/a | n/a | -US$550m |
| Mar 31 2025 | n/a | n/a | -US$578m |
| Dec 31 2024 | US$9m | US$921k | -US$522m |
| Sep 30 2024 | n/a | n/a | -US$533m |
| Jun 30 2024 | n/a | n/a | -US$483m |
| Mar 31 2024 | n/a | n/a | -US$539m |
| Dec 31 2023 | US$39m | US$675k | -US$615m |
報酬と市場: Marianneの 総報酬 ($USD 7.83M ) は、 US市場 ($USD 5.22M ) の同規模の企業の平均を上回っています。
報酬と収益: Marianneの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Marianne De Backer (57 yo)
3.4yrs
在職期間
US$7,834,045
報酬
Dr. Marianne De Backer, MSc, Ph. D. MBA, is a CEO & Director of Vir Biotechnology, Inc., since April 03, 2023 and also serves as its President from March 4, 2026. She served as Independent Director at Kron...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 3.4yrs | US$7.83m | 0.59% $ 10.6m | |
| Executive VP | 4yrs | US$1.69m | 0.0049% $ 87.3k | |
| Co-Founder & Scientific Advisor | 10.7yrs | データなし | データなし | |
| Co-Founder & Scientific Advisor | no data | データなし | データなし | |
| Senior VP | 3.6yrs | データなし | 0.037% $ 657.4k | |
| Executive VP & Chief Technical Operations Officer | 1.6yrs | データなし | データなし | |
| Executive VP & Chief Scientific Officer | 2.8yrs | データなし | データなし | |
| Head of Investor Relations | no data | データなし | データなし | |
| Senior Vice President of Corporate Communications | 1.7yrs | データなし | データなし | |
| Executive VP & Chief Human Resources Officer | 2.7yrs | データなし | データなし | |
| Executive VP & Chief Business Officer | 3.3yrs | US$4.54m | データなし |
3.3yrs
平均在職期間
61yo
平均年齢
経験豊富な経営陣: VIRの経営陣は 経験豊富 であると考えられます ( 3.3年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 3.4yrs | US$7.83m | 0.59% $ 10.6m | |
| Co-Founder & Scientific Advisor | no data | データなし | データなし | |
| Co-Founder & Scientific Advisor | no data | データなし | データなし | |
| Independent Director | 10yrs | US$182.86k | 0.019% $ 346.8k | |
| Independent Chairman | 9.8yrs | US$184.98k | 0.63% $ 11.4m | |
| Scientific Advisor | no data | データなし | データなし | |
| Scientific Advisor | 7.7yrs | US$23.92k | データなし | |
| Independent Director | 6.1yrs | US$159.98k | 0.013% $ 225.4k | |
| Scientific Advisor | no data | データなし | データなし | |
| Scientific Advisor | no data | データなし | データなし | |
| Scientific Advisor | no data | データなし | データなし | |
| Director | less than a year | データなし | 0.0095% $ 170.0k |
6.9yrs
平均在職期間
72.5yo
平均年齢
経験豊富なボード: VIRの 取締役会 は 経験豊富 であると考えられます ( 6.9年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/14 12:20 |
| 終値 | 2026/09/14 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Vir Biotechnology, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16
| アナリスト | 機関 |
|---|---|
| Madhu Kumar | Baird |
| Huidong Wang | Barclays |
| Etzer Darout | Barclays |